Francesca Isabella De-Simone et al.
PloS one, 10(6), e0129694-e0129694 (2015-06-11)
Patients undergoing immune modulatory therapies for the treatment of autoimmune diseases such as multiple sclerosis, and individuals with an impaired-immune system, most notably AIDS patients, are in the high risk group of developing progressive multifocal leukoencephalopathy (PML), an often lethal